An Autolus Therapeutics cell therapy has won FDA approval for treating an aggressive blood cancer. It’s the biotech’s first approved product and just the second CAR T-treatment for adults who have ...

More than a third of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with the CAR T-cell therapy obecabtagene autoleucel (obe-cel) remained in remission at a ...

The National Institute for Health and Care Excellence (NICE) has recommended obecabtagene autoleucel (obe-cel) for adults aged 26 and older with relapsed or refractory B-cell precursor acute ...

Development of B cells, white blood cells that make antibodies, follows a progression of stages: common lymphoid progenitors, pre-pro-B cells, pro-B cells, pre-B cells, immature B cells, and then more ...

Findings published today in Nature Cancer from Charles Mullighan, MBBS (Hons), MSc, MD, deputy director of the St. Jude Comprehensive Cancer Center, Department of Pathology, and collaborators show ...

Please provide your email address to receive an email when new articles are posted on . 40% of responders remained in remission without subsequent stem cell transplantation or other therapy. Ongoing ...

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy that is manufactured in 48 hours using ...

Obecabtagene autoleucel showed effective outcomes in both younger and older adults with relapsed/refractory B-cell acute lymphoblastic leukemia, with similar remission rates and chimeric antigen ...